One of the most widely used drugs for the treatment of BC ER+ is tamoxifen, a selective ER modulator that competes with its natural ligand, estradiol (E2), an estrogen hormone playing a critical role in breast tissue growth, development, and function [2]. This evidence concerns the gene ESR1 and breast cancer.